A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors

NCT05346484 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

66

Enrollment

INDUSTRY

Sponsor class

Stopped Portfolio prioritization

Conditions

Solid Tumor
Solid Carcinoma
Solid Tumor, Adult
Metastatic Cancer
Advanced Solid Tumor
Cholangiocarcinoma
Bile Duct Cancer

Interventions

BIOLOGICAL: CF33-hNIS
BIOLOGICAL: Pembrolizumab
DRUG: Modified FOLFOX

Sponsor

Imugene Limited